Abstract
Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Current Pharmaceutical Biotechnology
Title:Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Volume: 17 Issue: 7
Author(s): Radzislaw Mierzynski, Dominik Dluski, Dorota Darmochwal-Kolarz, Elzbieta Poniedziałek-Czajkowska, Bozena Leszczynska-Gorzelak, Zaneta Kimber-Trojnar, Agnieszka-Wankowicz and Jan Oleszczuk
Affiliation:
Keywords: Intra-uterine growth retardation, fetal programming, cardiovascular diseases, insulin secretion, insulin resistance, metabolic syndrome.
Abstract: Intra-uterine growth retardation (IUGR) represents one of the major problems in perinatal medicine. IUGR is one of main causes of perinatal mortality and morbidity. A huge number and variety of established and possible causes of IUGR have been described. There are currently no data about effective treatment of this fetal condition. IUGR has been described to be strictly involved in fetal programming. Fetal programming is the general idea, which tells us how during development of the embryo and fetus significant physiological parameters can be shaped by environmental events. A link between the intra-uterine growth retardation and the risk of developing type 2 diabetes, obesity and cardiovascular disease postnatally has been well documented. The aim of this paper is to present an overview of the current knowledge of IUGR effects on development of hypertension and cardiovascular diseases, impact on insulin secretion and resistance, diabetes mellitus and metabolic syndrome. The influence of intrauterine growth retardation on predisposition to obesity and adipose dysfunction was also described.
Export Options
About this article
Cite this article as:
Mierzynski Radzislaw, Dluski Dominik, Darmochwal-Kolarz Dorota, Poniedziałek-Czajkowska Elzbieta, Leszczynska-Gorzelak Bozena, Kimber-Trojnar Zaneta, Agnieszka-Wankowicz and Oleszczuk Jan, Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders, Current Pharmaceutical Biotechnology 2016; 17 (7) . https://dx.doi.org/10.2174/1389201017666160301104323
DOI https://dx.doi.org/10.2174/1389201017666160301104323 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Receptor for AGEs (RAGE) as Mediator of NF-kB Pathway Activation in Neuroinflammation and Oxidative Stress
CNS & Neurological Disorders - Drug Targets Potential Targets for Intervention in Radiation-Induced Heart Disease
Current Drug Targets Arterial Hypertension and Kidney Circulation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Oxidative Stress in the ICU
Current Nutrition & Food Science Advances in the Topical Treatment of Diabetic Foot Ulcers
Current Diabetes Reviews Vaccination Against High Blood Pressure
Current Pharmaceutical Design Medicinal Properties of Mangiferin, Structural Features, Derivative Synthesis, Pharmacokinetics and Biological Activities
Mini-Reviews in Medicinal Chemistry Synergy of microRNA and Stem Cell: A Novel Therapeutic Approach for Diabetes Mellitus and Cardiovascular Diseases
Current Diabetes Reviews Quantification of Shear Stress and Geometric Risk Factors in Carotid Atherosclerosis: Review and Clinical Evidence
Recent Patents on Medical Imaging Microencapsulation: Techniques, Food Applications and Pest Control
Recent Patents on Engineering Development of a UGT1A1 Reporter Gene Assay for Induction Studies: Correlation Between Reporter Gene Data and Regulation of UGT1A1 in Human Hepatocytes
Drug Metabolism Letters A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Potentials and Cytochrome P450-Mediated Interactions Involving Herbal Products Indicated for Diabetes Mellitus
Drug Metabolism Letters Recent Studies and Patents in Salivary Protein Biomarkers for Diabetes
Recent Patents on Biomarkers Advanced Glycation End Products and Cardiovascular Disease
Current Diabetes Reviews RAGE: A Potential Target for Aβ-Mediated Cellular Perturbation in Alzheimers Disease
Current Molecular Medicine Menopause and Non-Alcoholic Fatty Liver Disease: A Review Focusing on Therapeutic Perspectives
Current Vascular Pharmacology Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design Microvascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Involvement of Trace Elements in the Pathogenesis of Prion Diseases
Current Pharmaceutical Biotechnology